Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: Safety, immunogenicity and persistence of antibody responses

Abstract The immunogenicity and reactogenicity of booster vaccination with GSK Biologicals’ hexavalent DTPa-HBV-IPV/Hib vaccine was assessed in toddlers aged 12–18 months previously primed with the same combination ( N = 341), or with DTPa-IPV/Hib and HBV administered separately ( N = 102; Trials 21...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2007-01, Vol.25 (6), p.1055-1063
Main Authors: Heininger, U, Sänger, R, Jacquet, J.-M, Schuerman, L
Format: Article
Language:English
Subjects:
Allergy and Immunology
Antibody persistence
Applied microbiology
Bacterial diseases
Biological and medical sciences
Child
Child, Preschool
Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage
Diphtheria-Tetanus-Pertussis Vaccine - adverse effects
Diphtheria-Tetanus-Pertussis Vaccine - immunology
DTPa-HBV-IPV/Hib
Ent and stomatologic bacterial diseases
Female
Fundamental and applied biological sciences. Psychology
Haemophilus influenzae
Haemophilus Vaccines - administration & dosage
Haemophilus Vaccines - adverse effects
Haemophilus Vaccines - immunology
Hepatitis B Vaccines - administration & dosage
Hepatitis B Vaccines - adverse effects
Hepatitis B Vaccines - immunology
Hepatitis B virus
Human bacterial diseases
Human viral diseases
Humans
Immunization, Secondary - trends
Immunologic Memory - immunology
Infant
Infectious diseases
Male
Medical sciences
Microbiology
Miscellaneous
Pediatric booster vaccination
Poliovirus Vaccine, Inactivated - administration & dosage
Poliovirus Vaccine, Inactivated - adverse effects
Poliovirus Vaccine, Inactivated - immunology
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viral diseases
Viral hepatitis
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The immunogenicity and reactogenicity of booster vaccination with GSK Biologicals’ hexavalent DTPa-HBV-IPV/Hib vaccine was assessed in toddlers aged 12–18 months previously primed with the same combination ( N = 341), or with DTPa-IPV/Hib and HBV administered separately ( N = 102; Trials 217744/059 and 217744/096). Antibody persistence at age 4–6 years was also assessed in children who had received a 4th consecutive dose of DTPa-HBV-IPV/Hib vaccine or separate DTPa-IPV/Hib and HBV vaccines in this study and in another study conducted under similar conditions in Germany. Prior to booster vaccination in the second year of life, antibody concentrations and seroprotection rates were similar irrespective of the primary vaccine used. One month after boosting with DTPa-HBV-IPV/Hib, substantial antibody increases were observed against all vaccine antigens indicative of previous immune priming. Seropositivity and booster response rates against all antigens were 97.4–100%. Reactogenicity following booster vaccination with DTPa-HBV-IPV/Hib was similar regardless of the primary regimen used. Three to four years after administration of the 4th DTPa-HBV-IPV/Hib dose, >90% vaccinees had persistent protective antibody concentrations against diphtheria, hepatitis B, Hib and the three poliovirus types. Anti-tetanus antibody concentrations were ≥0.1 IU/ml in 76.4% subjects and seropositivity for pertussis antibodies ranged from 34.5% for PT to 98.9% for FHA. In conclusion, the combined hexavalent DTPa-HBV-IPV/Hib vaccine is immunogenic and safe when used for boosting in the second year of life, regardless of the primary vaccine used, and offers sustained protection during early childhood and beyond.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2006.09.060